Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL17: Ibrutinib vs Venetoclax + Obinutuzumab vs Ibrutinib + Venetoclax in Untreated CLL
NCT04608318Phase 3Active, not recruiting
- Sponsor
- German CLL Study Group
- Start
- Mar 2021
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 13
01
Overview
A Phase 3 trial of ibrutinib, venetoclax, obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Mar 2021; status: active, not recruiting.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04608318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608318.